New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Friday, November 13, 2026

Back to the front page

From X

Serenity on X

Just to state the nuances of my opinion: Jensen is irreplaceable to $NVDA. No other CEO can visit a chicken shop in Korea, noodle shop in Japan And rally hundred of billions of capital and supply chain commitment into Nvidia’s next technological vision. As for Nvidia: the their roadmap is intact, their existing commitment and revenues are still preserved under Jensen’s leadership. They’ll still be around 5-10 years from now, given how fundamentally important they are to AI supply chains. Under a new leader they can still continue growing if AI demand is intact and maintain their current lines. But I don’t know anyone who can possibly think that under anyone else, whether it’s Tim Cook or an accountant: That Nvidia could compound 70% capacity constrained growth Y/Y, without a leader like Jensen making these transformational bets. As for AI implications: I’m heavily bullish directionally, given AI is the most transformational technology in human history. - I expect some potential slowdown in Nvidia’s ecosystem. I don’t think an accountant can make the same aggressive level of commitments to Neoclouds or supply chains in Taiwan, Korea, Japan beyond existing architectures. Then rally the capital and trust to make it happen. - I do expect the next CEO to be more politically aligned with Washington in restricting China GPU access - I also see the next CEO being less supportive of open weight models (positive for OpenAI/Anthropic) - I’m less optimistic on $NVDA maintaining their competitive advantages against $AMD, $AVGO, and hyperscalers. One person doesn’t break the AI trade, I expect companies from optics to memory to still outperform. However, my confidence in the next leg of Nvidia’s growth, beyond their current roadmap, has been shaken without Jensen Huang.

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

SILC · long

Silicom LTD

Silicom (SILC) is pitched as inexpensive on its existing hardware business, with upside framed as a cheap call option.

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.